Media headlines about Biostage (NASDAQ:BSTG) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biostage earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.599082986097 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Biostage (BSTG) traded down 3.187% on Thursday, hitting $0.322. 94,111 shares of the stock were exchanged. Biostage has a 52-week low of $0.22 and a 52-week high of $1.42. The company has a 50-day moving average price of $0.39 and a 200-day moving average price of $0.36. The firm’s market cap is $12.54 million.

Biostage (NASDAQ:BSTG) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03). On average, equities research analysts anticipate that Biostage will post ($0.42) EPS for the current fiscal year.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Biostage in a research report on Monday, August 7th.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at

In related news, insider Saverio Lafrancesca bought 100,000 shares of Biostage stock in a transaction on Thursday, August 24th. The stock was acquired at an average price of $0.37 per share, with a total value of $37,000.00. Following the acquisition, the insider now directly owns 293,998 shares of the company’s stock, valued at $108,779.26. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.30% of the stock is owned by insiders.

Biostage Company Profile

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

Insider Buying and Selling by Quarter for Biostage (NASDAQ:BSTG)

Receive News & Ratings for Biostage Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc. and related companies with's FREE daily email newsletter.